Cyendiv®

Indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

Indications

Indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Brand Names Cyendiv®
Active ingredients nintedanib esylate
Available SKUs 100 mg, 150 mg

For more Information, Visit Cyendiv Website www.cyendiv.com/ipf/
Pack Insert PDF iconCyendiv PI dated 25 March 2020.pdf